Key Highlights
- First-quarter 2026 total revenue was $13.4 million, down 5% year over year, but recurring revenue rose 9% to $12.6 million and represented 94% of total revenue.
- The ALLY installed base reached approximately 205 systems as of March 31, 2026, with a backlog of 11 units; the combined ALLY-plus-legacy installed base of 440 systems grew 12% year over year.
- Net income of $36.3 million was driven almost entirely by non-cash and non-operating items tied to the collapsed Alcon merger, not by underlying operating improvement.
- With the merger overhang removed, LENSAR's opportunity rests on converting its 11-unit ALLY backlog into placements and lifting utilization.
LENSAR, Inc. (NASDAQ:LNSR), maker of the ALLY Robotic Cataract Laser System, closed a first quarter dominated by fallout from a terminated Alcon acquisition rather than pure operating momentum. Total revenue slipped 5% year over year to $13.4 million, yet recurring revenue reached $12.6 million, a record 94% of sales, as procedure volume and installed base kept expanding even while system placements paused.
Why LENSAR Is Back on Investors' Radar
LENSAR, Inc. (LNSR) spent much of the past year as a takeover target rather than a standalone growth story. Alcon Research, LLC agreed in March 2025 to acquire the Orlando-based maker of robotic cataract lasers, only for the deal to collapse on March 16, 2026 after the FTC signaled it intended to sue to block it on antitrust grounds. With the merger behind it, LENSAR is again being judged on its own results, and its May 8, 2026 first-quarter report offers the first clean look at the business.
Total revenue fell slightly as system sales cratered during the deal-uncertainty period, yet procedure, lease and service revenue kept growing, and the ALLY installed base continued to expand, a maturing, annuity-like revenue stream layered under a still-lumpy equipment business.
Inside LENSAR's Robotic Cataract Surgery Franchise
LENSAR designs, manufactures and markets laser systems used by ophthalmic surgeons to perform femtosecond laser-assisted steps of cataract surgery, including capsulotomy creation, lens fragmentation and astigmatism-correcting incisions. Its flagship product, the ALLY Robotic Cataract Laser System, commercially introduced in 2022, is a compact, single-console platform that lets surgeons perform the laser portion of a cataract procedure in an office-based surgical suite rather than a hospital operating room, lowering overhead and improving workflow. ALLY incorporates LENSAR's proprietary Streamline software and IntelliAxis imaging technology.
Revenue comes from system sales, the upfront laser price; lease revenue for financed access; and procedure and service revenue tied to usage. LENSAR emphasizes "recurring revenue," the latter three combined, as the better gauge of demand, distinct from the volatile timing of new placements.
LENSAR (LNSR) and the Aftermath of the Terminated Alcon Deal
Alcon Research, LLC, a unit of Swiss eye-care giant Alcon Inc., signed a definitive merger agreement with LENSAR on March 23, 2025. The deal drew FTC scrutiny in May 2025. In March 2026, LENSAR and Alcon mutually agreed to terminate the agreement after concluding U.S. regulatory approval was unlikely by the outside date, and LENSAR retained a $10.0 million deposit Alcon had placed with the company.
That deposit, booked as acquisition income in the first quarter of 2026, along with a $23.9 million non-cash gain on warrant liabilities, explains why LENSAR reported net income of $36.3 million versus a net loss of $27.3 million a year earlier. CEO Nick Curtis said first-quarter results "decreased slightly as compared to the first quarter of 2025, primarily driven by the uncertainty and disruption in the market around the Alcon transaction." Investors need to separate this one-time noise from the recurring trends that will drive the stock.
First-Quarter 2026 Operating Performance
For the three months ended March 31, 2026, LENSAR reported total revenue of $13.4 million, down from $14.2 million a year earlier. System revenue fell to $836,000 from $2.6 million, the clearest sign of placement disruption during the merger process. Procedure revenue rose to $9.2 million from $8.3 million, lease revenue slipped to $1.7 million from $1.9 million, and service revenue rose to $1.7 million from $1.4 million. Recurring revenue of $12.6 million represented 94% of total revenue, up from 81%.
Worldwide procedure volume reached 54,094, up from 52,347, roughly 3% growth reflecting rising utilization even as placements paused. LENSAR placed 7 new ALLY systems, bringing the installed ALLY base to approximately 205 units at quarter-end, with a backlog of 11 more. The combined ALLY-and-legacy base rose to approximately 440 units, up 12% year over year, slower than the 39% ALLY placement growth and 48% ALLY base expansion posted for full-year 2025.
Revenue Quality, Margins, Cash and Balance Sheet
Gross profit was approximately $6.4 million on cost of revenue of $7.0 million, a gross margin near 47.5%, down from roughly 50.3% a year earlier. SG&A fell to $2.5 million from $11.1 million, though the prior period carried $4.4 million of acquisition costs; excluding those, underlying SG&A was roughly $6.9 million in both periods. R&D was $1.4 million versus $1.5 million. Operating expenses of $4.1 million produced operating income of $2.2 million, versus a $5.8 million operating loss a year earlier, flattered by the absence of acquisition costs rather than organic leverage.
LENSAR ended the quarter with cash, equivalents and investments of $13.5 million, down from $18.0 million, reflecting cash used to pay down payables tied to the terminated merger. The balance sheet carries no conventional bank debt; Series A Preferred Stock restricts debt above $1.0 million without holder consent. Total liabilities fell to $41.6 million from $83.7 million at year-end as warrant liabilities dropped to $16.2 million from $40.2 million, and equity turned positive at $10.8 million. LENSAR has issued no numeric 2026 guidance, though management expects recurring revenue to keep growing and placements to normalize.
Where Growth Could Come From Next
With the merger overhang removed, LENSAR's opportunity rests on converting its 11-unit ALLY backlog into placements and lifting utilization. Full-year 2025 showed the pre-disruption trajectory: revenue of $58.4 million, up 9%; recurring revenue of $46.3 million, up 15%; and procedure volume of 206,014, up roughly 22%. International expansion and converting legacy customers to ALLY are additional levers.
Material Risks Facing LENSAR Shareholders
LENSAR remains a small, single-product-family device company with a history of losses; the 2025 operating loss was $24.6 million and net loss $34.3 million. The abrupt Alcon termination, and the FTC's stated intent to challenge it, creates uncertainty about how partners view LENSAR's standalone prospects, and related litigation is a flagged possibility. LENSAR faces well-capitalized rivals with their own femtosecond lasers: Alcon Inc., Bausch + Lomb, Carl Zeiss AG and AMO, a Johnson & Johnson division. Bausch + Lomb expects to launch a second-generation platform, SeeLyra, in the second half of 2026, which LENSAR calls the first next-generation competitor to ALLY. Tariffs and component costs have pressured margin, and warrant liabilities mean net income can swing sharply with LENSAR's own share price.
Outlook
The upside case centers on recurring revenue, now 94% of sales, compounding as the ALLY base and procedure volumes grow while placements normalize. The base case is a company mid-reset in placements, with margin pressured by cost inflation and adjusted EBITDA near breakeven. The downside case involves slower placement recovery, intensifying SeeLyra competition, and continued cash use without debt capacity. None of this predicts where LNSR shares will trade; it reflects the range of outcomes in LENSAR's reported numbers.
Conclusion
LENSAR, Inc. (LNSR) enters the second half of 2026 with the Alcon overhang resolved and a recurring revenue base that grew through a disruptive stretch. A re-rating depends on whether placements and margin recover as management expects, and whether ALLY's lead holds against new femtosecond competition.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...